Risk Factors and Mechanisms of Recralization after Administration of antagonist for neuromuscular blocking agent.

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K18263
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55050:Anesthesiology-related
• Research Institution: Chiba University
• Principal Investigator: Muramatsu Takahiro 千葉大学, 医学部附属病院, 助教 (80807446)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: 筋弛緩管理 / 残存筋弛緩 / 再クラーレ化

Outline of Final Research Achievements

Neuromuscular blocking agents are essential drugs for surgical anesthesia, but residual neuromuscular blocking after surgery is a medical complication. Our previous studies found that elderly patients are at higher risk for one type of residual postoperative neuromuscular blocking, recuralization, and we predicted that obese patients would be at higher risk as well. We then predicted that obese patients would be at higher risk as well, so we planned to study obese patients, but were unable to do so adequately because of the interruption of research due to the coronavirus disaster. However, as a neuromuscular blocking researcher, I have been widely educating the public about the dangers of residual muscle relaxation by participating online in international conferences and giving invited lectures at academic conferences in Japan. We also investigated the actual situation of neuromuscular blocking management at Chiba University Hospital and published a paper on the subject.

Free Research Field

麻酔

Academic Significance and Societal Importance of the Research Achievements

筋弛緩薬は手術麻酔に必須の薬剤だが、術後の筋弛緩作用の残存は患者の不利益につながる医原性合併症である。我々はこれを防ぐため、どのような患者に残存筋弛緩のリスクが高いのかを調査した。また、患者要因のみならず、我々医療者も適切な管理を行うことが不可欠である。そこでその第一歩として、筋弛緩管理の現状を調査し、その改善方法の提案を含めて論文を執筆し、報告した。